Clinical Trial Update: The Use of Cytomegalovirus Cell Mediated Immunity to Optimize the Duration of Letermovir Prophylaxis in Hematopoietic Cell Transplant Recipients [NA]

View source ↗

Summary

Clinical trial investigating using cytomegalovirus cell-mediated immunity to optimize the duration of letermovir prophylaxis in hematopoietic cell transplant re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cytomegalovirus Infection

Drugs mentioned

• PREVYMIS (letermovir)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Cytomegalovirus Cell Mediated Immunity, Hematopoietic Cell Transplant | NA | Status: RECRUITING